1211TiPFAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

S. Symeonides; T.r.j. Evans; V. Coyle; A. Serrels; F. Thomson; D. Currie; S. Dillon; J. Paul; D.a. Fennell; C. Ottensmeier

doi:10.1093/annonc/mdx376.071

1211TiPFAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

S. Symeonides, T.r.j. Evans, V. Coyle, A. Serrels, F. Thomson, D. Currie, S. Dillon, J. Paul, D.a. Fennell, C. Ottensmeier

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Journal	Annals of Oncology
Volume	28
Issue number	suppl_5
DOIs	https://doi.org/10.1093/annonc/mdx376.071
Publication status	Published - 1 Sept 2017

Access to Document

10.1093/annonc/mdx376.071

http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx376.071/4109284/1211TiPFAKPD1-a-phase-IIIa-trial-of-FAK-defactinib

Cite this

@article{a46034cbe63e454780a2f1aa6efb625d,

title = "1211TiPFAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition",

author = "S. Symeonides and T.r.j. Evans and V. Coyle and A. Serrels and F. Thomson and D. Currie and S. Dillon and J. Paul and D.a. Fennell and C. Ottensmeier",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/annonc/mdx376.071",

language = "English",

volume = "28",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "suppl_5",

}

TY - JOUR

T1 - 1211TiPFAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

AU - Symeonides, S.

AU - Evans, T.r.j.

AU - Coyle, V.

AU - Serrels, A.

AU - Thomson, F.

AU - Currie, D.

AU - Dillon, S.

AU - Paul, J.

AU - Fennell, D.a.

AU - Ottensmeier, C.

PY - 2017/9/1

Y1 - 2017/9/1

U2 - 10.1093/annonc/mdx376.071

DO - 10.1093/annonc/mdx376.071

M3 - Meeting abstract

SN - 0923-7534

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

IS - suppl_5

ER -